You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DCR-PHXC

Showing 26 - 50 of 183
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

Adenocarcinoma Gastric, Gastrooesophageal Cancer Trial in Worldwide (Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701))

Recruiting
  • Adenocarcinoma Gastric
  • Gastrooesophageal Cancer
  • Ramucirumab (CYRAMZA®)
  • Tusamitamab ravtansine (SAR408701)
  • Bruxelles, Belgium
  • +22 more
Jan 16, 2023

Ovarian Carcinoma Trial in Tanta (Itraconazole capsule, Placebo)

Not yet recruiting
  • Ovarian Carcinoma
  • Itraconazole capsule
  • Placebo
  • Tanta, Egypt
    Tanta University, Faculty of Pharmacy
Oct 20, 2022

Breast Tumor Female Trial (AK105, Anlotinib HCl, Albumin Paclitaxel)

Not yet recruiting
  • Breast Neoplasm Female
  • (no location specified)
Jul 11, 2022

Color Doppler Ultrasound in Lacrimal Sac Space-occupying Lesions

Completed
  • Dacryocystitis; Chronic
  • +3 more
  • CDU and CT-DCG or CT examination
  • Wenzhou, Zhejiang, China
    Eye Hospital and School of Ophthalmology and Optometry,Wenzhou M
Aug 12, 2022

Metastatic Pancreatic Cancer Trial (Olaptesed pegol)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Olaptesed pegol
  • (no location specified)
Jul 19, 2022

CharactHer. ICORG 12-09, V3

Terminated
  • HER2-positive Breast Cancer
  • TNM Stage II-IV Breast Cancer
    • Dublin, Ireland
    • +1 more
    Jan 14, 2022

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Cancer Patients Trial in Jinan (Low-dose radiotherapy combined with conventional fractionated radiotherapy)

    Recruiting
    • Cancer Patients
    • Low-dose radiotherapy combined with conventional fractionated radiotherapy
    • Jinan, In Shandong Province, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Jun 7, 2023

    Dacryocystitis Trial in Mansoura (Pregabalin 150mg, Placebo)

    Completed
    • Dacryocystitis
    • Pregabalin 150mg
    • Placebo
    • Mansoura, Dakahlia, Egypt
      Department of Anesthesia, Mansoura University Hospitals
    Jul 12, 2022

    Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

    Not yet recruiting
    • Non-small Cell Lung Adenocarcinoma
    • Squamous Cell Carcinoma of Lung
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Jul 5, 2023

    Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Seoul (PBT and atezolizumab/bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Portal Vein Thrombosis
    • PBT and atezolizumab/bevacizumab
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Nov 15, 2022

    Hepatocellular Carcinoma Trial in Nanjing (cTACE, Dicycloplatin (TP21), Epirubicin)

    Recruiting
    • Hepatocellular Carcinoma
    • cTACE
    • +2 more
    • Nanjing, Jiangsu, China
      Zhongda Hospital, Southeast University
    Jul 22, 2022

    Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

    Not yet recruiting
    • Metastatic Extracranial Malignant Solid Neoplasm
    • +3 more
    • Intestinal Low Dose Radiotherapy-1Gy
    • +3 more
    • Shantou, Guangdong, China
      Cancer Hospital, Shantou University Medical College
    Oct 7, 2023

    NSCLC, Brain Metastases, EGFR Mutation Trial in Guangzhou (Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Gefitinib and Pemetrexed/platinum
    • Gefitinib mono-therapy
    • Guangzhou, Guangdong, China
      Sun Yat-sen University of Cancer Center
    Feb 19, 2022

    Squamous Cell Carcinoma of Head and Neck Trial in Spain, United States (REGN6569, Cemiplimab)

    Recruiting
    • Squamous Cell Carcinoma of Head and Neck
    • Los Angeles, California
    • +9 more
    Jun 20, 2022

    Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

    Recruiting
    • Ovarian Cancer
    • fluzopanib and bevacizumab
    • Chongqing, Chongqing, China
      Chongqing Cancer Hospital
    Sep 19, 2022

    Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA

    Not yet recruiting
    • Adrenal Cortical Carcinoma
    • +3 more
    • individualized mRNA neoantigen vaccine (mRNA-0523-L001)
    • Shanghai, Shanghai, China
      Ruijin hospital, Shanghai Jiao-Tong University School of Medicin
    Nov 19, 2023

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

    Recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • Combined therapy of anlotinib and aumolertinib
    • Kunming, Yunnan, China
      First Affiliated Hospital of Kunming University
    Oct 22, 2023

    Breast Cancer Trial (Injection of A166)

    Not yet recruiting
    • Breast Cancer
    • Injection of A166
    • (no location specified)
    Apr 20, 2022

    Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)

    Active, not recruiting
    • Metastatic Urothelial Cancer
    • Enfortumab vedotin
    • Beijing, China
    • +7 more
    Aug 23, 2022

    Advanced Solid Tumors Trial in United States (REGN7075, cemiplimab)

    Recruiting
    • Advanced Solid Tumors
    • San Francisco, California
    • +9 more
    Jan 30, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (camrelizumab& apatinib)

    Recruiting
    • Hepatocellular Carcinoma
    • camrelizumab& apatinib
    • Guangzhou, Guangzhou, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Sep 18, 2022

    Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Tucson (Cabozantinib + Atezolizumab)

    Recruiting
    • Pancreatic Cancer
    • Metastatic Pancreatic Cancer
    • Cabozantinib + Atezolizumab
    • Tucson, Arizona
      University of Arizona Cancer Center
    Dec 14, 2022

    Advanced Colorectal Cancer: A Real-world Study

    Active, not recruiting
    • Advanced Colorectal Cancer
      • Beijing, Beijing, China
      • +1 more
      Mar 9, 2022